



Date: December 15, 2022

To,
Listing Operations
BSE Limited,
P J Towers, Dalal Street,
Mumbai-400001, IndiaTo,
Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (E) Mumbai – 400051**Sub.: Submission of daily report in accordance with Regulation 18(i) of the SEBI (Buy-back of Securities) Regulations, 2018 ("Buy-back Regulations")****Ref.: Buy-back of Equity Shares of Windlas Biotech Limited (the "Company")**

Dear Sir(s),

Pursuant to provisions of Regulation 18(i) of the Buy-back Regulations, we hereby submit the daily report with respect to Equity Shares bought back by the Company on December 15, 2022:

Name of the Broker(s)	Number of Equity Shares Bought Back on December 15, 2022		Total Shares Bought Back	Average Price of Acquisition Rs.*
	BSE	NSE		
SMC Global Securities Limited	0	26,402	26,402	254.60
Total (A)	0	26,402	26,402	254.60
Cumulative Equity Shares bought as on Yesterday (B)				2,34,870
Less: Quantity Closed Out Today (C)				Nil
Quantity Closed Out as on Yesterday (D)				NA
Total Quantity closed out (C+D=E)				Nil
Total Equity Shares bought back as on 15.12.2022 (A) +(B) - (E)				2,61,272

Fund utilized for the Buy-back as on December 15, 2022:

Particulars	Amount in Rs.
Total amount earmarked for the Buy-back (Excluding Transaction Cost)	25,00,00,000.00
Total amount utilized on Buy-back on December 15, 2022 (Excluding Transaction Cost)	67,21,827.55
Cumulative amount utilized on Buy-back till December 15, 2022 (Excluding Transaction Cost)	6,75,37,863.10



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

Notes:

1. **Excludes Transaction Costs*
2. *Current reporting period is the day on which this report is being filed with the stock exchanges.*
3. *The above information is subject to settlement as per the existing rules for secondary market transactions of the Stock Exchanges and verification of Equity Shares bought back, where applicable.*
4. *For the purpose of this disclosure, 'Yesterday' shall refer to the last trading day.*

Please acknowledge the receipt and inform the members of the Exchange.

For Windlas Biotech Limited

Ananta Narayan Panda
Company Secretary & Compliance Officer